Hu Zhongjie, Liu Ying, Qiu Lixia, Fan Zuopeng, Nie Wei, Liang Shan, Jin Ronghua
Department of Hepatitis C & Toxic liver diseases, Beijing Youan Hospital, Capital Medical University, Beijing, the People's Republic of China.
Management center of medical record, Beijing Youan Hospital, Capital Medical University, Beijing, the People's Republic of China.
Virol J. 2015 Dec 18;12:220. doi: 10.1186/s12985-015-0451-9.
Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-α plus ribavirin combination therapy (PEG-IFNα/RBV). But the exact mechanisms remain unclear. The aim of this study was to investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFNα/RBV treatment.
One hundred twelve Chinese patients with chronic HCV 1b infection were enrolled and received a standard protocol of 48 weeks of PEG-IFNα/RBV therapy and 24 consecutive weeks of follow-up. Serial blood samples were obtained at pretreatment baseline, and again at weeks 2, 4, 8, 12, and 24 during therapy for the quantification of 70R and 70Q/H strains. Dynamic characteristics and association with early virological response (EVR), sustained virological response (SVR) and IL28B genotypes were analyzed.
Of the 112 patients enrolled in this study, 93.8% (105/112) were infected with mixture of 70R and 70Q/H strains before treatment. The 70Q/H strain was dominant in 20.5% of patients. 42.9% of patients with dominant 70Q/H exhibited EVR versus 88.6% of patients with dominant 70R (P < 0.001). Furthermore, 35.0% of patients with dominant 70Q/H exhibited SVR versus 77.4% with dominant 70R (P < 0.001). However, regardless of the dominant strain, virological response types or the IL28B SNP genotypes, 70Q/H strains always exhibited the same response to treatment as the 70R strains and the percentage of HCV harboring the 70Q/H substitution did not change significantly during treatment.
Although the ratio of 70Q/H to 70R is related to the virological response, 70Q/H strains always exhibited the same response as the 70R strains during PEG-IFNα/RBV treatment. Substitution of R70Q/H alone is not enough to lead to resistance to therapy. Positive selection for 70Q/H induced by IFNα was not observed.
丙型肝炎病毒(HCV)1b基因型核心蛋白中的氨基酸(aa)70位点替代(R70Q/H)已被证明是决定聚乙二醇化干扰素-α联合利巴韦林治疗(PEG-IFNα/RBV)耐药性的关键因素之一。但其确切机制仍不清楚。本研究的目的是调查野生型和突变型核心密码子70菌株对PEG-IFNα/RBV治疗的动态反应。
招募112例中国慢性HCV 1b感染患者,接受48周的PEG-IFNα/RBV标准治疗方案,并连续随访24周。在治疗前基线以及治疗期间的第2、4、8、12和24周采集系列血样,用于定量70R和70Q/H菌株。分析动态特征以及与早期病毒学应答(EVR)、持续病毒学应答(SVR)和IL28B基因型的关联。
在本研究纳入的112例患者中,93.8%(105/112)在治疗前感染了70R和70Q/H菌株的混合物。70Q/H菌株在20.5%的患者中占主导地位。70Q/H占主导的患者中42.9%出现EVR,而70R占主导的患者中这一比例为88.6%(P<0.001)。此外,70Q/H占主导的患者中35.0%出现SVR,而70R占主导的患者中这一比例为77.4%(P<0.001)。然而,无论占主导的菌株、病毒学应答类型或IL28B单核苷酸多态性基因型如何,70Q/H菌株对治疗的反应始终与70R菌株相同,并且在治疗期间携带70Q/H替代的HCV百分比没有显著变化。
尽管70Q/H与70R的比例与病毒学应答相关,但在PEG-IFNα/RBV治疗期间,70Q/H菌株对治疗的反应始终与70R菌株相同。单独的R70Q/H替代不足以导致对治疗的耐药性。未观察到IFNα诱导的70Q/H阳性选择。